<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79227">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074059</url>
  </required_header>
  <id_info>
    <org_study_id>03-CL-1201</org_study_id>
    <secondary_id>4R44HL107000-02</secondary_id>
    <nct_id>NCT02074059</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates</brief_title>
  <official_title>A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Windtree Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Windtree Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of
      aerosolized surfactant, specifically lucinactant for inhalation, administered in escalating
      inhaled doses to preterm neonates 29 to 34 weeks gestational age who are receiving nasal
      continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS),
      compared to neonates receiving nCPAP alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Lucinactant for Inhalation</measure>
    <time_frame>Day 7</time_frame>
    <description>Assessed during dosing by recording adverse reactions, oxygen saturation levels, and serum electrolytes; and following dosing by recording complications of prematurity and signs of worsening respiratory distress as evidenced by need for increased respiratory support and supplemental oxygen</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Aerolized lucinactant (Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose: Lucinactant for inhalation with nCPAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (Medium Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium Dose: Lucinactant for inhalation with nCPAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose: Lucinactant for inhalation with nCPAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (High Dose, Extension 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose, Extension 1: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (High Dose, Extension 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose, Extension 2: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nCPAP alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nCPAP therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lucinactant for Inhalation</intervention_name>
    <description>Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)</description>
    <arm_group_label>Aerolized lucinactant (Low Dose)</arm_group_label>
    <arm_group_label>Aerosolized lucinactant (Medium Dose)</arm_group_label>
    <arm_group_label>Aerosolized lucinactant (High Dose)</arm_group_label>
    <arm_group_label>Aerosolized lucinactant (High Dose, Extension 1)</arm_group_label>
    <arm_group_label>Aerosolized lucinactant (High Dose, Extension 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nCPAP alone</intervention_name>
    <description>nCPAP therapy</description>
    <arm_group_label>nCPAP alone</arm_group_label>
    <other_name>nasal continuous positive airway pressure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent from a legally authorized representative

          -  Gestational age 29 to 34 completed weeks (34 weeks 6 days) post menstrual age (PMA)

          -  Successful implementation of controlled nCPAP within 90 minutes after birth

          -  Spontaneous breathing

          -  Chest radiograph consistent with RDS

          -  Need for moderate levels of supplemental oxygen and nCPAP to maintain oxygen
             saturation of 88% to 95% for at least 30 minutes within the first 21 hours after
             birth

        Exclusion Criteria:

          -  Heart rate that cannot be stabilized above 100 beats/minute within 5 minutes of birth

          -  Recurrent episodes of apnea occurring after the initial newborn resuscitation period
             (ie, 10 minutes after birth) requiring intermittent positive pressure breaths using
             inflating pressures above the set CPAP pressure administered manually or mechanically
             through any patient interface

          -  A 5 minute Apgar score &lt; 5

          -  Major congenital malformation(s) and cranial/facial abnormalities that preclude
             nCPAP, diagnosed antenatally or immediately after birth

          -  Other diseases or conditions potentially interfering with cardiopulmonary function
             (eg, hydrops fetalis or congenital infection such as TORCH)

          -  Known or suspected chromosomal abnormality or syndrome

          -  Prolong rupture of membranes (PROM) &gt; 2 weeks

          -  Evidence of hemodynamic instability requiring vasopressors or steroids for
             hemodynamic support and/or presumed clinical sepsis

          -  Need for endotracheal intubation and mechanical ventilation

          -  Has been administered: another investigational agent or exposure to an
             investigational medical device, any other surfactant agent, steroid treatment after
             birth
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>29 Weeks</minimum_age>
    <maximum_age>34 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Segal, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Windtree Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women and Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children at IU Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Neonatology Associates</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 19, 2015</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
